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Abstract Membrane type-1 matrix metalloproteinase (MT1MMP, MMP-14) is a unique protease that cleaves extracellular
proteins, activates proMMPs, and initiates intracellular signalling. MCF-7 cells are non-invasive and deficient in MT1MMP, MMP-2, and MMP-9 expression. We created an
MCF-7 cell line (C2) that stably produces active MT1-MMP
and demonstrated increased ERK1/2 phosphorylation. MAPK
inhibition in this cell line showed an inverse relationship in
MMP-2 and MMP-9 transcripts where levels of these genes
increased and decreased, respectively. Using invasive MDAMB 231 cells that endogenously produce MT1-MMP and
have naturally high pERK levels, we demonstrated the identical inverse relationship between MMP-2 and -9 transcript
and protein levels, suggesting that this novel relationship is
conserved amongst MT1-MMP positive breast cancer cells.
To further analyze the relationship between MMP-2 and -9
levels, we chemically inhibited activation and catalytic activity of MT1-MMP using a furin and MMP inhibitor, respectively, to show that interference with the functions of MT1MMP induced changes in MMP-2 and 9 transcript levels that
were always inverse of each other, and likely mediated by
differential transcriptional activity of the NF-κB transcription
factor. Furthermore, we analyzed the functional consequences
of these expression changes to show MMP, and in particular
ERK, inhibition decreased migration and invasion using 2D
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culture, and inhibits the formation of an invasive phenotype in
Matrigel 3D culture. This study demonstrated a novel inverse
transcriptional relationship between MMP-2 and -9 levels and
MT1-MMP activity that have functional consequences, and
also showed that increases in the levels of MMPs does not
necessarily correlate with an invasive phenotype.
Keywords MT1-MMP . MMP-2 . MMP inhibition . Cell
migration . 3D culture . ERK signalling

Introduction
Matrix metalloproteinase 14 (MMP-14), also known as membrane type-1 (MT1)-MMP, is unique amongst the family of
MMPs due to its unique regulation of cell movement. Cell
migration in multicellular organisms requires passage between
cells and through the extracellular matrix (ECM). Such cell
migration through a barrier, termed invasion, is often protease
dependent (Bateman et al. 2009; Järveläinen 2009). Cell invasion is fundamental during embryogenesis and plays a critical
role in adult wound healing, pregnancy, and disease
(Bourboulia and Stetler-Stevenson 2010). The roles played by
cytoskeletal and cell adhesion molecules in cell movement have
been well described by many in vitro assays, but those played
by MMPs are confounding (Lambert et al. 2004). The activity
of potent MMPs, such as gelatinases MMP-2 and -9, cleaves
ECM proteins and thus it was believed facilitated cell movement (Klein and Bischoff 2011). The enzymatic activity of
MMPs is in turn inhibited by a family of four secreted inhibitors, the tissue inhibitors of MMPs (TIMPs) (Lambert et al.
2004). The interactions of MMPs and TIMPs are complex
and need to be tightly regulated as they have functions beyond
ECM remodelling, including roles in the cell signalling and
morphology changes needed for cell movement (Frantz et al.
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2010; Hynes and Naba 2012). Here we examine MT-1 MMP’s
role in orchestrating these many cellular functions.
To date, 24 MMPs have been identified in vertebrates that
together can cleave all components of the ECM, but MMP
enzymatic activity alone is not enough to facilitate invasion
(Hotary et al. 2006; Sabeh et al. 2009). All MMPs are synthesized as inactive zymogens, proMMPs, whose activation requires the removal of the N-terminal pro-domain. Membranetype MMPs, including MT1-MMP, are activated intracellularly, with activation in the trans-Golgi principally by furin
through a protein-convertase-dependent mechanism (Seidah
et al. 2008). MT1-MMP is anchored at the cell membrane in
an active form (Sternlicht and Werb 2001), whereby secreted
proMMPs, such as the gelatinases, are activated extracellularly by other, already active proteinases, including membrane
tethered MT1-MMP. Active membrane bound MT1-MMP is
involved in a well described mechanism that activates
proMMP-2. This requires the formation of the MT1-MMP/
TIMP-2/proMMP-2 complex, where MT1-MMP is in the correct orientation to cleave the pro-peptide domain of proMMP2 and release the activated MMP-2 into the ECM (Itoh et al.
2001; Lehti et al. 2000). Additionally, the MT1-MMP/TIMP2/MMP-2 complex has been shown to subsequently activate
secreted proMMP-9 (Toth et al. 2003). Thus MT1-MMP is
involved in a well described functional relationship with
MMP-2 and MMP-9, and as such a mechanism that correlates
their expression levels likely exist.
Cell-surface MT1-MMP and TIMP-2 can also form an additional receptor/ligand complex whereby MT1-MMP initiates
the MAPK pathway, leading to downstream phosphorylation of
extracellular signal-regulated kinase (ERK1/2) (Pahwa et al.
2014; Sounni et al. 2010). Our previous work demonstrated
that optimal levels of active MT1-MMP, not just a global increase in MT1-MMP protein levels, are required for elevated
pERK levels (Cepeda et al. 2016). The localization of MT1MMP by its cytosolic C-terminal domain also plays a role in
both gelatinase activation and cell signalling. Membrane localization of MT1-MMP by its cytosolic domain is also important
in the regulation of cell migration and invasion as, together with
cortactin, is localized to invadopodia - cell membrane protrusions that serve as focal sites of ECM degradation (Poincloux
et al. 2009). MT1-MMP is thus perfectly poised to localize, and
co-ordinate, ECM degradation and cell signalling activity in
cells situated to migrate or invade.
To investigate the contributions played by MT1-MMP in
regulating MMP-2 and MMP-9 transcript levels we used
MCF-7 and MDA-MB-231 cells and examined the effects of
altered MT1-MMP activation, MMP catalytic activity, and
ERK1/2 signalling (using furin inhibitor, BB94, and U0126,
respectively). Regardless of treatment, transcript levels of the
two gelatinases, MMP-2 and MMP-9, were always altered in
an inverse relationship. Functional analysis of these changes
in MMP levels was examined and only U0126 treatment, but
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not BB94 treatment, decreased cell migration as seen by
scratch and transwell assays. However, both U0126 and
BB94 treatment decreased cell invasion through a Matrigel
transwell assay, as well as the number of cell protrusions in
Matrigel 3D culture.

Materials and methods
Cell culture conditions
Human cell lines used are MCF-7 (ATCC® HTB-22™) and
MDA-MB-231 (ATCC® HTB-26™). The three MCF-7
breast cancer cell lines that stably overexpress MT1-MMP
were generated as previously describe (Cepeda et al. 2016) C1, expressed ~2500 fold increase in MT1-MMP mRNA
compared to MCF-7 parental cells, C2 ~ 1100 fold and C3
an ~11 fold increase. Cells were cultured in Dulbecco’s
Modified Eagles (DMEM)/F-12 medium (Thermo Fisher)
supplemented with 10% fetal bovine serum (FBS), 100 IU/
mL penicillin, 100 μg/mL streptomycin, in a humidified incubator at 37 °C and 5% CO2. Cells were maintained under
80% confluency and passaged accordingly using 0.25%
Trypsin-EDTA (Thermo Fisher).
Chemical inhibitors
The following inhibitors were used: U0126 (Santa Cruz
Biotechnology) which provided noncompetitive inhibition
with respect to ERK and ATP substrates (DeSilva et al.
1998). BB-94 (Santa Cruz Biotechnology) is an MMP substrate analog that binds to and inhibits the zinc ion in the MMP
catalytic site (Low et al. 1996). Furin Inhibitor I (Millipore)
binds the catalytic site of furin, blocking activity (Coppola
et al. 2008). Concentrations of respective inhibitors were as
follows: U0126 10 μM (Assent et al. 2015; D’Alessio et al.
2008), BB-94 10 μM (Itoh et al. 2001; Mori et al. 2002), and
Furin Inhibitor I 5 μM, 10 μM, and 20 μM.
RNA extraction and quantitative real-time PCR
Cells were seeded at a density of 1 × 106 cells/mL in 35 mm
cell culture plates (Corning) in 2 mL of DMEM/FBS medium
and were treated with U0126 (10 μM), BB-94 (10 μM), Furin
inhibitor I (5, 10, 20 μM), or DMSO (0.1%) for 24 h, lysed,
and RNA was collected using the RNeasy Kit (Qiagen).
cDNA was synthesized from 1 μg of RNA using qScript
cDNA supermix (Quanta). The relative mRNA levels of
MT1-MMP, MMP-2, MMP-9, and TIMP-2 were assayed by
qPCR using SensiFAST SYBR No-ROX Kit (FroggaBio) and
the CFX Connect™ Real-Time PCR Detection System (BioRad). mRNA levels were quantified by the ΔΔCT method
and displayed as fold change relative to MCF-7 or MDA-MB-
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231 breast cancer cells under normal culture conditions. The
level of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) mRNA was used as the internal control. Primer
sequences used were as follows;
MT1-MMP 5′-GCAGAAGTTTTACGGCTTGCA
5′- TCGAACATTGGCCTTGATCTC
MMP-2 5′- AGCTCCCGGAAAAGATTGATG 5′-CAGG
GTGCTGGCTGAGTAGAT
MMP-9 5′-CCTGGAGACCTGAGAACCAATC 5′-GATT
TCGACTCTCCACGCATCT
TIMP-2 5′-‘CGACATTTATGGCAACCCTATC 5’GCCGTGTAGATAAACTCTATATCC
GAPDH 5′-ACCCACTCCTCCACCTTTGA 5′-CTGT
TGCTGTAGCCAAATTCGT

Protein collection and immunoblotting
Cells were seeded and treated as with qPCR analysis.
Following 24 h of treatment cell lysates were collected and
total protein concentration was determined. Protein aliquots
(15 μg) were analyzed by immunoblotting with MT1-MMP,
β-actin, pERK or total ERK1/2 primary antibodies, followed
by incubation with the appropriate secondary HRPconjugated antibody and detected using SuperSignal West
Pico chemiluminescent substrate (Thermo Fisher).
Incubation with primary antibodies occurred overnight at
4 °C, and secondary antibodies for one hour at room temperature. Primary antibodies used were: Human MT1-MMP
(1:1000, AB6004, Millipore), pERK (1:2000, D13.14.4E),
total ERK1/2 (1:2000, 137F5) (Cell Signalling Technology),
and β-Actin (1:1000, C4). Goat anti-mouse IgG (H + L) (BioRad) and goat anti-rabbit IgG (H + L) (Thermo Fisher) HRP
conjugates were used as secondary antibodies (1:10,000).
Images were captured using the Molecular Imager®
ChemiDocTM XRS System (BioRad). Quantitative densitometric analysis of immunoblots was performed using
QuantityOne software (Bio-Rad). Band intensity was obtained for the MT1-MMP, β-Actin, phospho-ERK and total
ERK1/2 signal of each sample from three independent biological experiments. MT1-MMP pro- and active protein is presented as a ratio between each respective band intensity and βActin signal. ERK1/2 activation is presented as a ratio between pERK and total ERK1/2 band intensity normalized to
cells under control conditions.
Generation of proMMP-2 containing conditioned medium
ProMMP-2 conditioned medium (Cepeda et al. 2016) was
used to verify the efficiency of BB-94 in preventing activity
of MMPs of cleaving substrate as determined by gelatin
zymography analysis. In brief, conditioned medium (CM)
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containing proMMP-2 protein was created by transfecting
MCF-7 breast cancer cells with a cDNA construct coding
for MMP-2 protein. Since MCF-7 cells are MT1-MMP and
MMP-2 deficient, proMMP-2 CM generated in this way results in CM that contains predominately proMMP-2 protein.
Following a 24-h incubation period post transfection, cells
were washed with phosphate buffered saline (PBS) and incubated in serum free DMEM/F12 media for 24 h. This medium
conditioned with the soluble proMMP-2 product was then
collected, aliquoted, and stored at −80 °C for later use.
Gelatin zymography and reverse gelatin zymography
Gelatin zymography was performed as previously described
(Toth et al. 2001) and used to compare the levels of secreted
pro- and activate MMP-2 and MMP-9 in the medium of cells
following treatment with DMSO (0.1%), U0126 (10 μM), or
BB-94 (10 μM). Briefly, 15 μL of medium was loaded on a
10% polyacrylamide-0.1% gelatin gel and subjected to electrophoresis. After electrophoresis, the gels were incubated in
renaturing buffer (25% v/v Triton X-100 in dH2O), and then
incubated in developing buffer (0.5 M Tris–HCl, pH 7.8, 2 M
NaCl, 0.05 M CaCl2, and 0.2% Brij 35) at 37 °C for 48 h to
allow the MMPs to cleave the gelatin embedded within the
polyacrylamide gel. The gel was then stained with a 0.5%
Coomassie blue, 5% methanol, 10% acetic acid solution,
and progressively destained with a 20% methanol, 10% acetic
acid solution until bands that represent cleaved gelatin were
clearly visible. Images were taken using the Molecular
I m a g e r ® C h em i D o cT M X R S ( B i o R a d ) . R e v e r s e
zymography, which measures TIMP-2 activity, was performed by adding proMMP-2 conditioned medium to the
10% polyacrylamine-0.1% gelatin gel lacking denaturing detergents. Protein loading, renaturing, and staining process are
identical to gelatin zymography, however in reverse
zymography when the gel is de-stained it is clear, except for
dark blue banding that represents TIMP-2 proteins bound to
MMPs embedded in the gel, preventing their activity and
protecting the gelatin in that location.
Firefly luciferase transcriptional activity assay
Transcriptional activity of AP-1 and NF-κB was examined in
cells following inhibitor treatments. In brief, MCF-7, C2, and
MDA-MB-231 cells were seeded at a density of 3.0 × 104
cells/well in a 96-well culture plate (Corning) and incubated
for 24 h. Following incubation, cells were transfected using
Lipofectamine 2000 (Thermo Fisher), according to the manufacturer’s instructions, with luciferase reporter plasmids.
Either 0.2 μg of mammalian 3xAP1pGL3 (Addgene
Plasmid # 40342 for AP-1 transcription, or p1242 3xKB-L
(Plasmid #26699) for NF-κB transcription, were transfected
into cells. 24 h post transfection cells were subjected to
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treatment with DMSO (0.1%), U0126 (10 μM), or BB-94
(10 μM). 12 h later cells were lysed and treated with Firefly
Luciferase Glow Assay reagents (Thermo Fisher) according to
the manufacturer’s instructions. Luminescence was detected
using ModulusTM II Microplate Multimode Reader and the
GloMax®- Multi Detection System with Instinct® Software.
Scratch wound closure migration assay
To examine the effects of respective inhibitor treatment on cell
migratory potential, MDA-MB-231 breast cancer cells were
seeded at a density of 2.5 × 105 cells/mL in a 35 mm cell
culture dish (Corning) in 2 mL of DMEM/FBS medium and
allowed to form a monolayer for 24 h. Following incubation,
medium was aspirated and the monolayer was disrupted using
a 1000 μL pipette tip to create a wound down the length of the
culture dish. The remaining adhered cells were washed three
times with PBS (pH 7.2) to remove cell debris and then incubated with fresh DMEM 10% FBS, 1% pen/strep medium
containing treatment of DMSO (0.1%), U0126 (10 μM),
BB-94 (10 μM), or Furin Inhibitor I (20 μM). 2 h post wound
generation, using the Zeiss Observer. A1 AX10 microscope,
10 images were captured down the length of the scratch that
represent the ‘initial’ size of the wound for each respective
sample. The same area of the wound was imaged at 6, 12,
and 24 h following wound healing to examine the ability to
migrate into the wound space. Scratch closure was quantified
by measuring the width of the scratch each day and normalizing it to the initial size of the scratch. Scratch closure is presented as a mean percentage of the initial scratch size ± SEM.
Transwell cell motility assays
The migratory and invasive potential of MDA-MB-231 cells
was measured using 24-well 8 μm pore transwell inserts
(Corning). 2.0 × 104 cells were seeded on the upper chamber
of the transwell in serum-free medium treated with DMSO
(0.1%), U0126 (10 μM), or BB-94 (10 μM). Treated cells
were allowed to migrate (24 h) or invade (48 h) towards the
bottom chamber which contained DMEM/F-12 medium supplemented with 10% FBS serving as the chemoattractant.
Migration assays were performed with uncoated transwell inserts, whereas invasion assays were performed with inserts
coated with 20% Matrigel (BD Biosciences). Cells that migrated to the lower chamber of the transwell insert were fixed,
stained, and quantified as per Marshall, 2011. For quantification of invasion transwells, cells were fixed with 100% methanol and cells that did not invade through the transwell insert
and residual Matrigel were removed from the upper membrane surface with a damp cotton swab. Invaded cells were
then stained with a 0.5% crystal violet solution. Cells were
then imaged and 15 images were blindly taken per transwell
and quantified using ImageJ software (NIH, Bethesda).
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Three dimensional (3D) cell culture
MDA-MB-231 cells were embedded in 50% Matrigel
matrix (BD Biosciences) and processed for fluorescent
staining to assess changes in invasive morphological
features as described by Cvetković et al. (2014). In
summary, 35 mm Glass-bottom cell culture dishes
(MatTek) were coated with 50% Matrigel (BD
Bioscience) in serum-free medium. Once this layer solidified 2.5 × 10 4 cells seeded in 50% Matrigel in
serum-free medium was placed above the initial layer,
resulting in cells completely suspended in Matrigel. This
50% matrigel DMEM/F-12 serum-free medium was supplemented with DMSO (0.1%), U0126 (10 μM), or BB94 (10 μM). Cell colony morphology was monitored for
five days using bright-field microscopy (Leica
DM16000 B microscope with Leica DFC425 camera)
at 10X magnification, and representative 50 μm zstack images (2 μm interval) taken at random locations
across the matrix were captured using Leica MMAF
software (Metamorph®). Fluorescent staining procedure
was done as described in Cvetković et al. (2014) using
Alexa Fluor 633 phalloidin (1:100) and DAPI (1 μg/
mL) staining. Samples were imaged using a Nikon
A1R+ confocal microscope and NIS Elements software
(Nikon), capturing Z-stacks of approximately 100 μm.
To analyze and score morphology of cell colonies, images representing a field of view at 20× magnification,
were blindly analyzed using ImageJ software (NIH
Bethesda). Protrusions were defined as thin extensions
that emanated from a round cell colony. The number of
protrusions on all cell colonies in an image was counted, with longer protrusions counted as multiples of the
average protrusion length seen in that image to adjust
for the heterogeneity in size observed. Disseminations
were identified as small, round cells immediately adjacent to a larger colony. The score, representing the total
number of protrusions or total number of disseminations
for each treatment, was divided by the total number of
colonies to arrive at the final measurement of protrusions or disseminations per colony.
Statistical analysis
Statistical analysis and graphing was performed using
GraphPad Prism version 6.0. Data is presented as
mean ± SEM, where all experiments were comprised of at
least 3 biological replicates. One-way and Two-way
ANOVA followed by Dunnett’s post-hoc test were used and
are indicated respectively in each figure legend. Different
levels of statistical significance are denoted by a different
number of asterisks and are as follows: ****, p ≤ 0.0001,
***, p ≤ 0.001, **, p ≤ 0.01, *, p ≤ 0.05, ns, p < 0.05.
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Results
MT1-MMP expressing C2 and MDA-MB-231 cells facilitate
a pERK mediated change in MMP-2 and MMP-9 levels.
To investigate the effect of MT1-MMP on ERK signalling
and gelatinase levels, MCF-7 cells that stably express different
levels of MT1-MMP were used. Parental MCF-7 cells, which
Fig. 1 MAPK signalling
mediated an inverse relationship
between MMP-2 and -9 expression in MT1-MMP positive breast
cancer cells. a) Parental MCF-7
breast cancer cells, and MT1MMP clonal cell lines (C1, C2,
C3, see methods) were treated
with the MAPK inhibitor U0126
(10 μM) and the levels of
phospho-ERK were examined via
immunoblot (top). The numbers
in brackets indicate MT1-MMP
mRNA fold change of clones relative to MCF-7 parental cells
(=1). After U0126 treatment, the
levels of MMP-2 and -9 mRNA
were examined via qPCR and
graphically displayed as mRNA
fold change (bottom). b) MDAMB 231 breast cancer cells were
treated with U0126 (10 μM) and
the protein levels of pERK,
MMP-2, MMP-9, and TIMP-2
were analyzed via immunoblot,
gelatin zymography, and reverse
zymography, respectively (left).
After U0126 treatment, the levels
of MMP-2 and -9 mRNA were
examined via qPCR and graphically displayed as mRNA fold
change. c) MCF-7 together with
MCF-7 C2 (left), and MDA-MB
231 (right) breast cancer cells
were treated with U0126 (10 μM)
and the levels of MT1-MMP
protein were analyzed via immunoblot. Below the blots is the respective densitometry quantification of active and pro MT1-MMP
protein normalized to β-actin
levels. Means are presented ±
SEM, and were compared using
one-way ANOVA; ** p < 0.01;
**** p < 0.0001
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are naturally MT1-MMP deficient (Kohrmann et al. 2009),
and three stable clones that significantly differ in their stable
expression of MT1-MMP transcript from high (C1, ~2500
fold compared to MCF-7 parental cells), medium (C2,
~1100 fold) to low (C3, ~11 fold) were used (Cepeda et al.
2016). As western blot analysis (Fig. 1a) demonstrated that
cell line C2 had the highest level of pERK, most future work
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focused on this C2 line. C2 cells also had elevated MMP-2
and MMP-9 transcript levels compared to parental cells
(Fig. 1a, left graph). The addition of the MEK inhibitor
U0126 resulted in the decease of pERK in all cells, altered
MMP-2 and -9 transcript levels (Fig. 1a), and also lowered
MT1-MMP protein levels (Fig. 1c, left graph). This U0126
mediated decrease in MT1-MMP levels was mirrored by decreases in MMP-2 transcript levels, but opposite to an increase
in MMP-9 transcript levels (Fig. 1a).
To corroborate the MCF-7 and C2 data, MDA-MB-231 cells
were also used. Western blotting revealed that MDA-MB-231
contained pERK and active MT1-MMP protein, where pERK
levels were reduced by U0126 (Fig. 1b). Zymography analysis
of media removed from control MDA-MB-231 cells and those
treated with U0126 demonstrated a decrease in proMMP-9 protein levels, but an increase in proMMP-2 (Fig. 1b). Reverse
zymography showed that U0126 addition did not alter TIMP2 protein levels from MDA-MB-231 cells (Fig. 1b). In agreement with the protein data, qPCR revealed a significant decrease in MMP-9 transcript levels, and an increase in MMP-2
transcripts (Fig. 1b). As with the C2 cells, and in agreement
with the zymography data, MEK inhibition resulted in increased MMP-2, but decreased MMP-9 transcript levels in
MDA-MB-231 cells (Fig. 1b right).
Western blot analysis and band intensity quantification also
confirmed that while there is no active MT1-MMP in parental
MCF-7 cells, the amount of active MT1-MMP protein in C2
cells was related to the levels of pERK (Fig. 1c). Treatment of
C2 cells with U0126 significantly decreased the amount of
active MT1-MMP protein in C2 cells, and while such
U0126 treatment did decrease MT1-MMP levels in MDAMB-231 cells, the decrease was not significant (Fig. 1c).
Thus a pattern is seen with both C2 and MDA-MB-231 cells
where MT1-MMP/pERK levels mirror MMP-2 levels, with
MMP-9 always being opposite. Increasing active MT1-MMP
level is mirrored by increased MMP-9 levels but accompanied
by a decrease in MMP-2. Interestingly this inverse relationship is also seen in other cells in the context of MT1-MMP
levels. Hs578T cells are MT1-MMP positive cells that endogenously produce low levels of pERK1/2, and as such display
an inverse relationship regarding MMP-2 and -9 expression
(data not shown) that relates to their low levels of pERK
(Cepeda et al. 2016).
Inhibition of MMP activity, or interference of proMT1MMP activation, in both C2 and MDA-MB-231 cells
mediated an inverse relationship between MMP-2 and
MMP-9 transcript levels.
Having seen a relationship between MT1-MMP, MMP-2
and MMP-9 levels we then sought to investigate the importance of the activity of MT1-MMP on the levels of MMP-2
and MMP-9. Parental MCF-7 cells, known to be MT1-MMP
deficient, incubated with proMMP-2 containing media could
not activate proMMP-2 protein (Fig. 2a). Conversely, C2 cells

M. A. Cepeda et al.

incubated with proMMP-2 containing media produced an active 63 kDa MMP-2 band, a band which was eliminated upon
the addition of BB-94, demonstrating that this activation was
dependent on MMP activity (Fig. 2a). Western blot analysis of
MT1-MMP protein levels revealed that levels of active MT1MMP present in C2 cells was increased significantly by BB94 addition, but pERK levels were not (Fig. 2b and quantified
below). qPCR showed significant increases in the levels of
MT1-MMP and MMP-9 transcript levels in C2 cells treated
with BB-94, but a significant decrease in MMP-2 (Fig. 2c).
Western blot analysis of MDA-MB-231 cells treated with BB94 MMP inhibitor displayed no change in pERK levels (as
seen with C2 cells), and a non significant increase in the levels
of active and inactive MT1-MMP protein (Fig. 2d and
quantified to the right). In agreement with the trends seen with
the protein data, qPCR revealed significant increases in MT1MMP, and MMP-9 transcript levels, but a significant decrease
in MMP-2 (Fig. 2e).
While the use of BB-94 allowed us to examine the
necessity of MT1-MMP enzymatic activity, we next
wanted to investigate the effect of altering the activation
of proMT1-MMP using a furin inhibitor. As previously
observed, Western bot analysis demonstrated no detectable levels of MT1-MMP in parental MCF-7 cells
(Fig. 3a). However, while active MT1-MMP was present in C2 cells, the level was decreased in a dosedependent manner by furin inhibitor – a pattern also
seen for pERK levels in C2 cells (Fig. 3a).
Quantification confirmed that furin significantly decreased both the level of active MT1-MMP protein
and pERK levels (Fig. 3a graphs on right). In agreement with the observation that MMP-9 levels mirror
that of active MT1-MMP, qPCR showed a significant
decrease in MMP-9 transcript levels, but an increase in
the levels of MMP-2 in C2 cells treated with furin inhibitor
(Fig. 3b). Similarly, in MDA-MB-231 cells, the addition of
furin inhibitor decreased, though not significantly, active
MT1-MMP levels, and significantly decreased pERK levels
(Fig. 3c and quantified to the right). qPCR analysis of these
MDA-MB-231 cells revealed a significant decrease in MMP9 transcript levels, but an increase in MMP-2 levels (Fig. 3d),
again demonstrating the inverse relationship between MMP-2
and -9 mediated by MT1-MMP function.
MEK signalling inhibition decreased NF-κB transcription
in C2 and MDA-MB-231 cells.
Towards investigating the inverse relationship between
MMP-2 and MMP-9 transcript levels that are mediated by
active MT1-MMP or pERK levels, a luciferase gene reporter
assay was used to assess the transcriptional activity of AP-1
and NF-kB transcription factors. Treatment of parental MCF7 cells with U0126 or BB94 did not alter AP-1 nor NF-kB
transcription (Fig. 4a). Treatment of C2 cells with U0126 or
BB94 did not alter transcription of AP-1, but the AP-1
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Fig. 2 BB-94 inhibition of MMP proteolytic activity caused a change in
MMP-2/−9 and MT1-MMP transcript, but not pERK levels. a) MCF-7
and C2 cells were cultured in serum-free media (control) or with MMP-2
conditioned media (CM) and treated with DMSO (as a control) or BB-94
(10 μM) to analyze subsequent proMMP-2 activation via gelatin
zymography. Only C2 cells were capable of proMMP-2 activation, as
seen by presence of the active isoform of MMP-2, which was prevented
with the incubation with BB-94. b) MCF-7 and C2 cells were treated with
BB-94 (10 μM) and the levels of MT1-MMP and phospho-ERK protein
were analyzed via immunoblot. Below the blots is the respective densitometry quantification of active and pro MT1-MMP, and phospho-ERK,
normalized to β-actin and total ERK levels, respectively. c) MCF-7 and

C2 cells were treated with BB-94 (10 μM) and the levels of MT1-MMP,
MMP-2 and -9 mRNA were examined via qPCR and displayed as mRNA
fold change. d) MDA-MB 231 cells were treated with BB-94 (10 μM)
and the levels of MT1-MMP and phospho-ERK protein were analyzed
via immunoblot. To the right of the blot are the respective densitometry
quantification of active and pro MT1-MMP, and phospho-ERK, normalized to β-actin and total ERK levels, respectively. e) MDA-MB 231 cells
were treated with BB-94 (10 μM) and the levels of MT1-MMP, MMP-2
and -9 mRNA were examined via qPCR and displayed as mRNA fold
change. Means were presented ± SEM and analyzed via one-way
ANOVA; * p < 0.05; ** p < 0.01; *** p < 0.001

transcription of C2 cells was significantly lower than the parental MCF-7 cells (Fig. 4a). Treatment of C2 cells with
U0126 significantly decreased NF-kB transcription (Fig. 4a).
MDA-MB-231 cells treated with U0126 or BB94 did not alter
AP-1 transcription (Fig. 4b), however, treatment with U0126
(but not BB94) significantly decreased NF-kB transcription in
MDA-MB-231 cells (Fig. 4b bottom).

Inhibition of MAPK signalling activity inhibited both the
migration and invasion of MDA-MB-231 cells, while BB-94
inhibition of MMP activity only inhibited invasion.
Having demonstrated that both C2 and MDA-MB-231 cells
alter MT1-MMP and MMP-9 levels in a similar pattern, always
being opposite than that of MMP-2, we then wanted to investigate how such MMP differences would manifest themselves
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Fig. 3 Interference of MT1-MMP activation caused a change in MMP-2/
−9 expression. a) MCF-7 and C2 cells were treated with a furin inhibitor
(5,10, and 20 μM) and the levels of MT1-MMP and phospho-ERK protein were analyzed via immunoblot. To the right is the respective densitometry quantification of active and pro MT1-MMP, and phospho-ERK,
normalized to β-actin and total ERK levels, respectively. b) MCF-7 and
C2 cells were treated with a furin inhibitor (20 μM) and the levels of
MMP-2 and -9 mRNA were examined via qPCR and displayed as mRNA
fold change. Means were presented ± SEM and analyzed via one-way

ANOVA. c) MDA-MB 231 cells were treated a furin inhibitor (20 μM)
and the levels of MT1-MMP and phospho-ERK protein were analyzed
via immunoblot. To the right is the respective densitometry quantification
of active and pro MT1-MMP, and phospho-ERK, normalized to β-actin
and total ERK levels, respectively. d) MDA-MB 231 cells were treated
with a furin inhibitor (20 μM) and the levels of MMP-2 and -9 mRNA
were examined via qPCR and displayed as mRNA fold change. Means
were presented ± SEM and analyzed via one-way ANOVA; * p < 0.05; **
p < 0.01; *** p < 0.001

in modulating cell movement. MDA-MB-231 cells were used
as this cell line’s invasive properties have been well characterized. Confluent MDA-MB-231 cells were subject to a scratchwound-closure assay. Following the initial Bwound^, DMSO,
U0126, and BB94 treated cells all migrated to close the wound
to a similar state at 24 h; however, at the 12-h time point, U0126
treated cells showed a significant delay in migration and wound
closure (Fig. 5a). Cell migration was also measured via movement of cells through an 8 μm transwell pore. The addition of
U0126, but not BB-94, reduced the number of MDA-MB-231
cells that migrated through the transwell (Fig. 5b). A similar
assay was used where Matrigel was used to coat the transwell
pores, thus cell invasion was dependent on degradation of the
ECM. Both addition of U0126 and BB-94 reduced the number
of MDA-MB-231 cells that invaded through the pore, though
the addition of U0126 had a greater affect (Fig. 5c).
Inhibition of MAPK signalling and MMP activity both
decreased the number of cell protrusions, and both increased
the number of cellular blebs of MDA-MB-231 cells in 3D
Matrigel culture.
We wanted to account for any unintended cell structural changes that may have occurred due to altered ERK signalling or MMP
enzymatic activity after addition of the MEK inhibitor U0126 and
the MMP inhibitor BB-94. To examine changes in cell

morphology that are relevant to cell movement, MDA-MB-231
cells were embedded in Matrigel and treated with U0126 or BB94. By Day 5, morphological differences were apparent (Fig. 6a).
MDA-MB-231 cells treated with U0126 or BB-94 were significantly less protrusive (~ 2–3 protrusions per colony) than vehicle
treated MDA-MB-231 cells (~9 per colony) (Fig. 6a, and
quantified in b). Alternatively, MDA-MB-231 cells treated with
U0126 or BB94 all had significantly more disseminations
(Fig. 6a, and quantified in b). Immunofluorescence analysis examining nuclear and actin stains in these cells revealed that control
MDA-MB-231 cells were a network of elongated cells. Inhibition
by U0126 abolished the ability to form elongated processes,
resulting in small round single cells with very concentrated Factin. Inhibition of MMP catalytic activity with BB-94 resulted in
distinctly large aggregations of round cells, though some BB-94
treated MDA-MB-231 cells were still able to elongate (Fig. 6c).

Discussion
This study aimed to characterize the functional consequences
of an observed inverse relationship between MMP-2 and -9
transcript levels as they related to MT1-MMP function. We
examined the effects of MT1-MMP proteolytic and non-
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Fig. 4 MT1-MMP expressing
breast cancer cells demonstrated
differential activity of AP-1 and
NF-κB transcription factors.
MCF-7 and C2 cells (a) or MDAMB 231 cells (b) were transfected
with luciferase constructs controlled by either the AP-1 (left) or
NF-κB (right) promoter and
treated with DMSO (as a control),
U0126, or BB-94 (10 μM).
Following treatment, cells were
lysed and the levels of luciferin
produced was quantified using a
luminometer. Data is displayed as
mean luminescence (a.u.) ± SEM
and analyzed via one-way
ANOVA; * p < 0.05; ** p < 0.01;
*** p < 0.001; **** p < 0.0001.
Note how U0126 treatment only
affects NF-κB activity in MT1MMP positive breast cancer cells

Fig. 5 Inhibition of MAPK signalling and MMP activity decreased the
migratory ability of MDA-MB 231 cells. a) MDA-MB 231 cells were
seeded on a culture dish and allowed to reach confluency. Afterwards a
scratch was created in the middle of the monolayer, cell debris was
washed, and cells were incubated in media containing DMSO (as a control), U0126 or BB-94 (10 μM) for 24 h. During this incubation period,
the closure of the scratch was monitored using brightfield microscopy.
Scratch closure was quantified every day by measuring the distance of
migration using ImageJ and normalizing it to the initial scratch size. b,c)

MDA-MB 231 cells were treated with DMSO (as a control), U0126 or
BB-94 (10 μM) and plated on the upper surface of an uncoated transwell
insert (b, migration) or an insert coated with 20% matrigel (c, invasion) in
media without serum and allowed to migrate for 12 h to the bottom
compartment that contains media with 10% FBS. Cells that migrated to
the bottom compartment were quantified and displayed as relative migration to MDA-MB 231 cells incubated with 0.1% DMSO. Means are
presented ± SEM, and were compared using one-way ANOVA; **
p ≤ 0.01; **** p < 0.0001
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Fig. 6 Inhibition of MAPK
signalling and MMP activity
inhibited a protrusive phenotype
in Matrigel 3D culture. a)
Brightfield images of MDA-MB
231 cells 1, 3, and 5 days after
being embedded in Matrigel and
incubated in media containing
10% FBS supplemented with
DMSO (as a control), U0126 or
BB-94 (10 μM). Scale
bars = 100 μm. b) The number of
protrusions (left) or disseminations (right) per colony for each
treatment was blindly quantified
every day for 5 days during 3D
culture. Means are presented ±
SEM, and were compared using
one-way ANOVA; **, p ≤ 0.01;
****, p ≤ 0.0001. c)
Immunofluorescence analysis of
MDA-MB 231 cells 5 days after
being embedded in Matrigel and
incubated with DMSO (as a control), U0126 or BB-94 (10 μM).
Shown is a 3D volume view
merge at 20X (top) and 60×
(bottom) of DAPI (blue) and Factin channels (red). Scale
bars = 100 μm

proteolytic functions on orchestrating the movement of cells
by manipulating MT1-MMP activation (furin inhibitor),
MMP catalytic activity (BB-94), and ERK phosphorylation
(U0126). We used MCF-7 cells, which have low levels of
MT1-MMP and pERK (Kohrmann et al. 2009) as well as a

manipulated cell line (C2) and MDA-MB-231 cells, both of
which have relatively high levels of active MT1-MMP and
pERK (Cepeda et al. 2016; Kohrmann et al. 2009).
Increased active MT1-MMP proteins levels were always associated with increased pERK levels and increased MMP-9
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transcript levels, but with reduced MMP-2 transcript levels.
Moreover, cells with active MT1-MMP facilitated ERK phosphorylation and subsequent transcriptional activity of NF-κB.
Our results describe that inhibiting proMT1-MMP activation,
MMP activity, and/or ERK1/2 phosphorylation always resulted in an inverse change between MMP-2 and MMP-9 transcript levels. BB-94 treatment to inhibit MMP activity did not
significantly alter cell migration, though inhibition of ERK1/2
phosphorylation did. Conversely, both inhibition of ERK1/2
phosphorylation and MMP activity did inhibit cell invasion.
Proper ERK1/2 signalling is essential in many cellular processes including migration, proliferation, and apoptosis
(Fujioka et al. 2006). Subsequently, pERK can influence transcription factors, known to regulate the transcription of a
broad number of MMPs, with NF-κB, shown to specifically
regulate MT1-MMP and MMP-9, but not MMP-2 (Overall
and Lopez-Otin 2002). In this study, inhibiting ERK1/2 phosphorylation in both C2 and MDA-MB-231 cells resulted in
increased MMP-2, but decreased MMP-9 mRNA levels
(Fig. 1 and data not shown), indicating that the relationship
is conserved, at least between C2 and MDA-MB-231 cells.
Inhibition of ERK1/2 phosphorylation in C2 and MDA-MB231 cells also resulted in decreased NF-κB transcriptional
activity (Fig. 4), providing support for a role in pERK regulation of MMP-9 expression. A similar study performed by Lee
et al. (2013) in bladder cancer cells demonstrated that with
inhibition of ERK1/2 phosphorylation, both NF-κB transcriptional activity and MMP-9 expression decreased. Tandem decreases in MMP-9 and MT1-MMP mRNA levels following
inhibition of ERK1/2 phosphorylation have also been previously observed in rhabdomyosarcoma, fibrosarcoma, bladder,
colon, and prostate carcinoma cells (Tanimura et al. 2003).
In addition to being capable of regulating MMP transcript
levels, pERK influences a multitude of genes whose products
control the cytoskeleton, receptors, cytokines and growth factors. Inhibition of ERK1/2 phosphorylation in MDA-MB-231
cells resulted in decreased cell migration as measured by scratch
closure and transwell migration assays as well as decreased
invasion through a Matrigel coated transwell (Fig. 5). This
alone does not directly support a role for MT1-MMP in cell
movement, but does support previous work reporting the necessity of proper pERK signalling in order to achieve cell migration and invasion (Meloche and Pouysségur 2007). Towards
better understanding the role pERK levels may play in cell
movement in an MT1-MMP-dependent context, cell morphology was also examined. Acquisition of an invasive phenotype
requires modulation of cell-ECM interactions through cytoskeletal organization, proteolysis of the extracellular matrix, and
migration (Friedl and Wolf 2003). Upon inhibition of ERK1/2
phosphorylation in 3D cell culture, the morphology of MDAMB-231 breast cancer cells changed to become round with a
minimally protrusive phenotype. Fluorescence microscopy revealed a condensed and aggregated F-actin cytoskeletal
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network, contrasting that which forms in untreated cells
(Fig. 6). The reduction of protrusions following treatment with
U0126 could be attributed to deficiency in cytoskeletal organization as the formation of invadopodia requires actin polymerization to form a membrane protrusion that contains MT1MMP at the distal end (Artym 2006). Here, cells with decreased
pERK levels trend towards decreased active MT1-MMP and
proMMP-9 protein levels. With a reduction of MT1-MMP protein there is less ability to form functional invadopodia. Further,
MT1-MMP-mediated proMMP-2 activation would also be reduced, consequently reducing the activation of proMMP-9.
Therefore, cells with decreased pERK may have a lowered
ability to form invadopodia and lowered ability to degrade
ECM constituents as evidenced by reduced invasion through
Matrigel coated transwells.
Inhibition of MMP catalytic activity by BB94 in both C2
and MDA-MB-231 cells resulted in an increase in MT1-MMP
and MMP-9 transcript levels (Fig. 2), but decreased MMP-2
mRNA. In agreement with increased transcript levels, BB-94
inhibition also increased the level of active MT1-MMP protein,
though this increase was not significant. While addition of BB94 would result in inhibition of MMP catalytic activity, this
inhibition of the catalytic domain of MT1-MMP does not prevent signal transduction (D’Alessio et al. 2008; Sounni et al.
2010). Thus, despite MMP catalytic inhibition, MAPK activation can still occur, whereby subsequent activity of pERK could
be increasing the expression of MT1-MMP in both C2 and
MDA-MB-231 cells. This increase in MT1-MMP transcript is
not a result of transcriptional activity of transcription factors
AP-1 or NF-κB (Fig. 4), as their activity was not altered in
the presence of BB-94. MT1-MMP transcriptional control is
unique amongst MMP family members due to differences in
its promoter sequence, though pERK mediated activation is
often involved (Lohi et al. 2000; Sroka et al. 2007). MDAMB-231 cells are invasive cells that upon treatment with
MMP inhibitor BB-94, they drastically decreased their invasion
through a Matrigel coated transwell barrier (Fig. 5) and
displayed a less protrusive phenotype in 3D cell culture
(Fig. 6). Intriguingly, unlike treatment with U0126, the migratory ability of these cells is not impaired by BB94. This maintenance of pERK levels could preserve cell migratory machinery, but as migration alone does not require degradation of
ECM constituents, the changes observed in MMP-2 and
MMP-9 transcript levels are assumed to not impact this cell
motility event. Invasion on the other hand, was considerably
impacted by inhibition of all MMP catalytic activity. This is
evident based on decreased transwell invasion (Fig. 5) and a
noticeably less protrusive phenotype in 3D culture (Fig. 6).
Active MT1-MMP present on the cell surface is in part
dependent on intracellular activation of proMT1-MMP within
the Golgi and trans-Golgi network through a protein
convertase called furin (Seidah et al. 2008). Following treatment with Furin Inhibitor I, C2 cells exhibited an increase in
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proMT1-MMP levels, and an associated decrease in active
MT1-MMP levels, as well as decreased pERK protein levels
(Fig. 3). Furin inhibition in MDA-MB-21 cells, did not significantly alter MT1-MMP protein levels, but the trend was an
increase in proMT1-MMP levels, and an associated decrease
in active MT1-MMP as expected with inhibition of activation
of the pro-form. As with the C2 cells, furin inhibition did
result in decreased pERK levels. In addition to the decrease
in pERK levels seen after inhibition of furin in both C2 and
MDA-MB-231, this inhibition resulted in a decrease in MMP9 transcript levels, but increased MMP-2 transcript levels. The
consistency between the two cell lines regarding decreased
pERK signalling and associated decreases in MMP-9 transcript levels, but increases in MMP-2 levels, demonstrates a
conserved mechanism for influencing MMP-2/−9 expression.
In this study, furin inhibition linked proMT1-MMP activation to an inverse expression of the gelatinase genes. Similarly,
BB94 inhibition of MMP activity and U0126 inhibition of
ERK phosphorylation resulted in an inverse expression of
the gelatinase genes. As the levels of active MT1-MMP have
an affect on the enzymatic activity of other MMPs and ERK
phosphorylation, MT1-MMP is positioned as an important
player in coordinating both enzymatic events, cell signalling
cascades, and a functional transcriptional network with MMP2 and -9 that may be required for cell migration and invasion.
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